Vantictumab, formerly labeled as OMP18R5, represents the novel cloned antibody designed for specifically inhibit OPN receptor 18R5. Such approach is currently studied by Amgen regarding possible treatments in several orthopedic conditions, particularly situations involving excessive bone loss. Preclinical findings suggest Vantictumab can effectivel